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Case StudyMedical Nutrition Therapy for Chronic Kidney
Disease in Pregnancy: A Case ReportI
N THE UNITED STATES, THE
prevalence of chronic kidney dis-
ease (CKD) in pregnant women
has been reported to be 0.03% to
0.12%.1,2 In Mexico, in a third-level spe-
cialty hospital, the prevalence was
0.33%.3 Chronic kidney disease during
pregnancy has been associated with
higher risk of gestational hypertension,
preeclampsia, polyhydramnios, intra-
uterine growth restriction, preterm
birth, and low birth weight.3-5
Pregnancy involves many metabolic,
physiologic, and hemodynamic adap-
tations that are necessary for adequate
fetal development and growth. Women
with CKD have lower capacity to adapt
to these changes.6 Dialysis treatmentand its intensity during pregnancy
have been shown to decrease the clin-
ical adverse outcomes and improve
nutritional status.7
Medical nutrition therapy (MNT) in
CKD during pregnancy is essential, but
nutrient recommendations are very
general, and evidence is scarce.5,8,9
Although some guidelines exist, most
recommendations have been extrapo-
lated from CKD nutrition treatment
(without pregnancy) and from preg-
nancy nutrition recommendations.9,10
We present a case study from a
pregnant young woman with CKD
(stage V), receiving hemodialysis (HD).
CASE STUDY
Nutrition Assessment (First
Visit—14.3 Weeks of Gestation)
Client History. A 22-year-old woman
had a CKD diagnosis (stage V— Kidney
Disease Outcomes Quality Initiative)11
(7 months ago) from an unknown
cause. She was from a rural area, close
to Mexico City, where she was diag-
nosed and referred to a third-level
hospital in Mexico City. Hemodialysis
was started (10.5 h/wk). At 13.5 weeks
of gestation, she was referred to
another specialty hospital for follow-up
of her gestation. The departments
of Nephrology, Gynecology, Fetal-
Maternal Medicine, and Nutrition were
involved in her treatment. Hemodialysis
was continued during pregnancy and
was increased to 14 h/wk.
Food/Nutrition-Related History.
Before pregnancy, the patient never
received any nutritional guidance.
Usual dietary intake was recorded:
Energy intake was adequate (112%);
protein intake was excessive (1.9 g/kg
pregestational ideal body weight
[IBW]); sodium (Na) intake appeared
to be excessive, given that Na intake
from foods represented 100% of
needs, without considering table salt;OURNAL OF THE ACADand iron (Fe) intake (dietary and
supplemented) was adequate (92% of
recommended) (Table 1).
Since becoming pregnant, she re-
ported starting some positive lifestyle
changes (decreased sweetened car-
bonated beverage intake, minimum
salt use, and eating more meals at
home); nevertheless, high-energy-
density foods were frequently con-
sumed (eg, pastries, Mexican fried
foods). She ate three meals/day (only
one at home), and hermother prepared
her food.
Daily ﬂuid intake included natural
water (500 mL/day), 100% fruit juice
(250 to300mL/day), and lemon tea (480
mL/day). She reported drinking sweet-
ened carbonated beverages (250 to 500
mL/day), 4 times/wk.
She was taking several nutrition
supplements: folic acid (5 mg/day),
calcium (Ca; 300 mg/day), and vitamin
D3 (200 IU/day).
Anthropometric Measurements. The
patient was overweight when she
became pregnant (pregestational body
mass index, 27.08), and during the
ﬁrst visit she had an adequate weight
gain for gestational age (1.2 kg).12
Biochemical Data, Medical Tests, and
Procedures. Electrolyte and mineral
status were within normal ranges at
week 10.5. Biochemical data are
described in Table 2.
She had a diuresis of 1.8 L. She was
receiving 4,000 IU/HD session of
erythropoietin, and 100 mg/HD session
of elemental Fe.
Estimated Requirements
Energy. 30-35 kcal/dpregestational
IBW¼30-35 kcal62.8 kg13¼1,884-
2,198 kcal/dþ352 kcal/d (2nd trimes-
ter)¼2,236 to 2,550 kcal/d.
Protein. 1.2-1.5 g/d*pregestational
IBW¼1.2-1.562.8 kg13¼75.3-94.2 g/
dþ10 g/d¼85.3-104.2 g/d.9,10EMY OF NUTRITION AND DIETETICS 213
Table 1. Energy, macronutrient, vitamin, and mineral intake throughout pregnancy for a woman with chronic kidney disease
receiving medical nutrition therapya
First
trimesterb
Second
trimesterc
Third
trimesterd Reference intake10,18
Gestational age (wk) 13.3 24.2 30.5
Energy (kcal/d) 2,869 2,281 1,873 Individualized
Protein (g/d) 122.5 83.9 91.1 75.3-94.2 (1st trimester)
85.3-104.2 (2nd and 3rd trimesters)e
Carbohydrates (g/d) 376.9 288.8 247.5 175 g
Carbohydrates (%) 50.0 49.7 52.4 45-65
Fiber (g/d) 34.0 23.8 19.9 28
Fat (g/d) 113.0 92.7 59.2 —
Fat (%) 33.7 35.9 28.3 20-35
SFAf (g/d) 26.8 26.1 18.2 —
SFA (%) 8.0 10.1 8.7 —
MUFAg (g/d) 34.5 29.7 18.0 —
MUFA (%) 10.3 11.5 9.0 —
Vitamin C (mg/d) 61.2 117.7 41.7 170
Vitamin A (mg/d) 327.4 177.2 659.9 800
Vitamin A supplementation (mg) — 450 450
Folate (dietary folate equivalents)
(mg/d)
532.9 200.3 153.5 1,800
Folic acid supplementation (mg) 5,000 6,000 6,000
Iron (mg/d) 25.5 10.2 14.7 200
Iron supplementation (mg/d) 160 160 460
Calcium (mg/d) 1,437.1 1,002.2 806.7 1,000-1,200
Calcium
supplementation (mg/d)
300 550 550
Potassium (mg/d) 2,656.8 1,690.5 2,525.1 2,512h or Individualized
Sodium (mg/d) 2,503.3 1,484.7 958.7 2,000-3,000
Phosphorus (mg/d) 1,570.4 1,392.6 1,493.5 1,200 or individualized (labs)
Magnesium (mg/d) 295.2 302.4 271.4 200-300
aNutrient analysis was obtained with Food Processor SQL software (version 10.4, 2008, ESHA Research).
bUsual intake with detailed quantities and ingredients.
c2-d food record.
dTwo multiple-pass 24-h recalls.
e1.2-1.5 g/kg pregestational ideal body weight (IBW); þ 0 g/d (1st trimester) or þ 10 g/d (2nd and 3rd trimesters).
fSFA¼saturated fatty acids.
gMUFA¼monounsaturated fatty acids.
h40 mg/kg pregestational IBW.
PRACTICE APPLICATIONSNutrition Diagnosis
Excessive protein intake (NI, 5.7.2
[Nutrient Intake category from the
Academy of Nutrition and Dietetics’
Nutrition Care Process terminology])
(1.9 g/kg pregestational IBW) related to
lack of knowledge regarding nutrition
and CKD and undesirable food choices,214 JOURNAL OF THE ACADEMY OF NUTRITas evidenced by proteinuria (1,036 mg/
24-h urine).
Undesirable food choices (NB, 1.7
[Behavioral category from the Academy
of Nutrition and Dietetics’ Nutrition Care
Process terminology]) related to eating
away from home and a complicated
schedule because of HD sessions wereION AND DIETETICSevidencedbyhigh intakeofhigh-energy-
density and high-Na foods.
Nutrition Intervention
MNT Objectives:
1. Promote adequate intake of
energy, protein, and other nu-
trients to promote optimal fetalFebruary 2016 Volume 116 Number 2
Table 2. Biochemical data about renal function, electrolyte and mineral status, anemia, and hepatic function throughout
pregnancy for a woman with chronic kidney disease receiving medical nutrition therapy
Biochemical marker First trimester Second trimester Third trimester
Gestational age (wk) 10.5 16.5 23.3 27.2 31.3 32.5 34.2
Glucose (mg/dL)a 81 105 73 78 — 73 137
Oral glucose tolerance test:
0 min/60 min/120 min (mg/dL)
— 103/91/105 — — 72/67/95
Blood urea nitrogen (BUN; mg/dL)b 29 36 28 32 37 42 38
Creatinine (mg/dL)c 5.2 4.3 3.7 4.2 4.4 5.6 5.1
Uric acid (mg/dL)d 4.1 4.7 2.9 4.1 3.8 5.4 5.3
Creatinine clearance (mL/min) — 6.04 4.5 6.3 6.9 3.5 —
Sodium (mEq/L)e 135.0 134.8 139.0 134.0 134.0 137.0 135.0
Potassium (mEq/L)e 4.5 5.1 4.6 5.4 4.5 4.9 5.1
Chloride (mEq/L)e 98 101 103 97.5 98.1 100 98.9
Magnesium (mg/dL)f 2.2 2.2 2.1 2.2 2.0 2.2 1.7
Calcium (mg/dL)g 8.9 9.5 9.1 9.8 8.9 8.8 8.0
Hemoglobin (g/dL) 6.1 9.3 9.1 9.4 8.1 7.3 7.6
Hematocrit (%) 19.7 28.5 28.2 28.1 24.1 21.7 23.1
Proteinuria (mg/24 h) — 1,036 — — 976 640 —
Aspartate aminotransferase (IU/L) 7 7 7 9 10 15 12
Alanine aminotransferase (IU/L) 5 7 9 9 8 13 8
Total bilirubin (mg/dL) 0.2 0.2 0.2 0.3 0.3 0.3 0.8
Direct bilirubin (mg/dL) 0.1 0.1 — 0.1 0.1 0.1 0.2
Indirect bilirubin (mg/dL) 0.1 0.1 — 0.2 0.2 0.2 0.5
aTo convert mg/dL glucose to mmol/L, multiply mg/dL by 0.0555. To convert mmol/L glucose to mg/dL multiply by 18. Glucose of 108 mg/dL¼6 mmol/L.
bTo convert mg/dL BUN to mmol/L, multiply mg/dL by 0.357. To convert mmol/L BUN to mg/dL, mg/dL, multiply mmol/L by 2.8. BUN of 11.2 mg/dL¼4 mmol/L.
cTo convert mg/dL creatinine to mmol/L, multiply mg/dL by 88.4. To convert mmol/L creatinine to mg/dL, multiply mmol/L by 0.0113. Creatinine of 0.9 mg/dL¼80 mmol/L.
dTo convert mg/dL uric acid to mmol/L, multiply mg/dL by 59.5. To convert mmol/L uric acid to mg/dL, multiply mmol/L by 0.017. Uric acid of 5 mg/dL¼297.5 mmol/L.
eSodium mEq/L¼mmol/L, potassium mEq/L¼mmol/L, chloride mEq/L¼mmol/L.
fTo convert mg/dL magnesium to mmol/L, multiply mg/dL by 0.4114. To convert mmol/L magnesium to mg/dL, multiply mmol/L by 2.431. Magnesium of 2.43 mg/dL¼1 mmol/L.
gTo convert mg/dL calcium to mmol/L, multiply mg/dL by 0.25. To convert mmol/L calcium to mg/dL, multiply mmol/L by 4.01. Calcium of 10 mg/dL¼2.5 mmol/L.
PRACTICE APPLICATIONSgrowth and to meet nutrient
needs according to CKD and he-
modialysis treatment.
2. Increase awareness about the
importance of improvement
of food choices for perinatal
health andmaintaining adequate
electrolyte and mineral status.
Nutrition Prescription
Nutrition Plan. Energy: 2,000 kcal/
d (considering fewer HD sessions than
indicated for pregnancy and being
overweight), and 99 g/d protein (1.4 g/
kg pregestational IBWþ10 g/d) were
recommended.
Macronutrients. Fifty-ﬁve percent
carbohydrates, 19% protein, and 26%
lipids were recommended.
Fluid. No restriction of ﬂuids was
instituted.February 2016 Volume 116 Number 2Food and/or Nutrient Delivery
Decreased Protein Intake. The
patient was asked to eliminate high-
phosphorus foods, except for dairy
products that were recommended.
Moderate Na intake (2,000 g/d)
and potassium (K) restriction (foods
providing >250 mg/serving size) were
recommended, as well as eating ﬁve
meals/day. The patient was told to
continue with nutrient supplements
(Fe, folic acid, Ca, vitamin D3).
Nutrition Education
The importance of MNT for her condi-
tion was explained, as well as risks
and complications associated with her
disease. Food sources with high Na, K,
and phosphorus content were dis-
cussed. We also explained the nutrition
plan with the different choices fromJOURNAL OF THE ACADeach food group. An example of a 1-day
menu with the recommended food
groups and serving sizes was provided
to the patient.
Nutrition Monitoring
Nutrition monitoring ensued every 2
to 4 weeks.Follow-up
Nutrition Assessment and Mon-
itoring. The patient moved to Mexico
City from Tuesday to Friday with her
mother.Mother still cooks for her during
breakfast and dinner; lunch was pre-
pared by the housekeeper. The patient’s
food intake schedule varies according
to activities, especially during HD days.
Primary positive nutrition changes
during pregnancy included decreasedEMY OF NUTRITION AND DIETETICS 215
Table 3. Weight gain during pregnancy and classiﬁcation according to the
Institute of Medicine guidelines12
Gestational week Weight gain (kg) Weekly weight gaina Interpretation
14.3 1.2 — —
18.3 0 0 kg Insufﬁcient
22.2 1.8 0.46 kg Excessive
24.5 1.3 0.56 kg Excessive
27.5 3.2 1.06 kg Excessive
29.5 1.4 0.7 kg Excessive
31.5 0.5 0.25 kg Adequate
aRecommended weekly weight gain in overweight women: 0.23-0.33 kg.12 Pregestational weight¼79 kg.
PRACTICE APPLICATIONSintake of sweetened carbonated bev-
erages and fried or high-fat Mexican
food, select low-fat cooking methods,
increased vegetable intake, and
decreased intake of high-Na, high-
phosphorus, and other high-fat foods.
At the end of pregnancy, she reported
good adherence to the nutrition
plan. The patient was successful in
increasing the number of meals (4-5
meals/day). Fluid intake was main-
tained at 1,000 to 1,100 mL/day.
In general, her energy intake tended
to decrease. Total protein, carbohy-
drate, and fat intake were signiﬁ-
cantly reduced during pregnancy. Her
estimated Na intake from food sources
decreased from 2,500 mg/d to 958
mg/d. Potassium was maintained
within the recommended intake.
Phosphorus intake was decreased
from the ﬁrst trimester to the secondFigure 1. Weight gain during pregnancy, ac
216 JOURNAL OF THE ACADEMY OF NUTRITtrimester, but it appeared to be on the
upper limit. Iron intake (dietary and
supplement) was low during the sec-
ond trimester, achieving adequate
intake until the third trimester,
because of an increase in Fe dose to
400 mg/HD session (Table 1).
Folic acid, vitamin D3, and erythro-
poietin supplementation was main-
tained throughout pregnancy. A
multivitamin was added at 22.2 weeks
of gestation that provided 1,500 IU
vitamin A, 200 mg vitamin C, 250 IU
vitamin D3, 1 mg folic acid, 250 mg Ca,
and 60 mg Fe. Physical activity was
increased; mainly, the patient used the
stationary bike during her HD sessions
(4 days/wk).
From 22 weeks of gestation, the pa-
tient’s weight gain per week of gesta-
tion was accelerated (Table 3 and
Figure 1). The interdialytic weight gaincording to Institute of Medicine guidelines.
ION AND DIETETICSrange was between 2.2 and 2.5 kg,
which is higher than recommended.
Fetal growth was reported to be
adequate, except at week 30.2, when
the fetus was classiﬁed as large for
gestational age (LGA; estimated fetal
weight percentile, 81), and poly-
hydramnios was diagnosed.
Blood urea nitrogen (BUN), uric
acid, and creatinine were within goals
throughout pregnancy; BUN was
always maintained at less than 50
mg/dL. Sodium, K, chloride, magne-
sium, and Ca were within normal
range during pregnancy; phosphorus
was not measured. Proteinuria was
decreased from 1,036 mg/day to
640 mg/day (Table 2). Residual renal
function was maintained (range, 800
to 1,850 mL/24-h urine output). No
physical evidence of overhydration
was observed.
Impaired glucose tolerance was
diagnosed with a 75-g oral glucose
tolerance test (OGTT) performed at 16.5
weeks of gestation.14 A second OGTT
was performed at 31.3 weeks, with a
normal result. Blood pressure was
maintained within normal ranges.
Anemia was present during the
pregnancy, with Hb values less than 10
mg/dL (100 g/L; range, 6.1 to 9.4 mg/dL
[61 to 94 g/L]), and hematocrit be-
tween 19.7% and 28.5%, respectively.
Primary Nutrition Diagnosis
during Follow-up
Excessive carbohydrate intake (NI,
5.8.2) related to impaired glucoseFebruary 2016 Volume 116 Number 2
Maternal and fetal Perinatal outcome Newborn
Optimal
outcomes
Blood urea nitrogen,
potassium, and sodium
serum levels maintained
Alive newborn Normal anthropometric indices at birth
(10th-90th percentile)
Blood pressure within normal
ranges throughout pregnancy
Newborn classiﬁed
as adequate for
gestational age
Proteinuria was reduced
(1,036-640 mg/24 h urine)
No intrauterine
growth restriction
No preeclampsia
Normal fetal growth during
1st and 2nd trimesters
Adverse
outcomes
Impaired glucose tolerance at
2nd trimester
Preterm birth
(gestational age:
34.2 wk)
Clinical diagnoses: respiratory distress
syndrome, hyperbilirrubinemia, patent
ductus
arteriosus, sepsis, neuroinfection, and severe
pulmonary bronchodysplasia
Anemia Apgar 4/9 Suboptimal growth rate during
hospitalization
Polyhydramnios Low birth weight (1,900 g) 43 d in neonatal intermediate/
intensive care
Large for gestational age
fetus at 30.2 wk
Borderline low thorax
circumference (29 cm)
Figure 2. Perinatal outcomes: Optimal and adverse.
PRACTICE APPLICATIONStolerance, as evidenced by altered
fasting glucose (103 mg/dL).
Imbalance of ﬂuids (NI, 5.5) prob-
ably was related to insufﬁcient HD
therapy (14 h/wk) and irregular urine
output as evidenced by excessive
interdialytic weight gain and adequate
fetal growth.
Inadequate Fe intake (NI, 5.10.1) (85%
of recommendation) (from diet and
supplementation) during the second
trimester was related to higher re-
quirements attributable to HD sessions,
erythropoietin use, and pregnancy, as
evidenced by low hemoglobin and
hematocrit values (9.1 to 9.4 g/dL
[91 to 94 g/L], and 28.1% to 28.5%,
respectively).Nutrition Intervention
Energy and protein intake recommen-
dations were maintained throughout
pregnancy (2,050 kcal/d and 99 g/d,
respectively). High-quality protein
was emphasized. At 22.2 weeks’
gestation, a carbohydrate-controlled
nutrition plan was recommended (45%February 2016 Volume 116 Number 2carbohydrates, 230 g/d), with 35% of
lipids, because of the diagnosis of
impaired glucose tolerance.
Basic carbohydrate counting was
taught. Food sources of carbohydrates,
serving sizes, the even distribution of
carbohydrates throughout the day, as
well as the importance of consistency
of carbohydrate eating between days
was discussed.
Healthy food selection was always a
primary nutrition education subject.
Moderate restriction of Kwas continued
throughout the pregnancy, as well as a
decrease in high-sugar, high-fat food
sources. Individual goals were to
decrease juices, pastries, and chips.
Phosphorus intake was controlled. The
importance of eating high-Fe food
sources also was emphasized.Clinical Outcomes
Pregnancy was interrupted because of
premature rupture of membranes at
34.2 weeks’ gestation. A male new-
born was born, with a weight of 1,995
g (z-score 0.8), length of 44 cmJOURNAL OF THE ACAD(z-score 0.4), and head circumfer-
ence 32 cm (z-score 0.4).15 His Apgar
score was 4/9. He was hospitalized
with respiratory distress syndrome,
multi-etiology hyperbilirubinemia,
patent ductus arteriosus, late sepsis,
neuroinfection, and severe pulmonary
bronchodysplasia. Growth rate during
hospitalization (43 d) was sub-
adequate (Figure 2).
DISCUSSION
MNT for CKD during pregnancy is essen-
tial but remains a challenge. This case
demonstrates that a multidisciplinary
treatment may help attenuate the high-
risk proﬁle of CKD during pregnancy.
Our patient did not develop hyper-
tensive disorders in pregnancy. Even
though impaired glucose tolerance
was observed during the second
trimester, low glucose values were
observed on a third trimester OGTT. A
preterm birth of 34.2 weeks was a
positive outcome, considering the re-
ported mean of 32 weeks of gestation
in this population.5 Although the
newborn was classiﬁed as low birthEMY OF NUTRITION AND DIETETICS 217
PRACTICE APPLICATIONSweight (<2,500 g), anthropometric
indices at birth were all adequate
(10th to 90th percentiles).15
Nutrition intervention was successful
in reducing the patient’s intake of high-
energy foods, sweetened carbonated
beverages, juices, and in controlling Na,
K, and phosphorus intake. The patient
was able to increase her vegetable
intake. The intervention appeared to
have a positive effect on electrolyte and
mineral status. Considering past reports,
HD for these patients should be given
for a total of 20 h/wk,16,17 although this
patient received HD for 14 h/wk, and
BUNwasmaintained at less than 50mg/
dL.8 Residual renal function was stable,
and anuria was avoided.
One of the main challenges of MNT
was the recommendation of energy
intake. For CKD in pregnancy receiving
HD treatment, energy intake may be
estimated as 30 to 35 kcal/kg.5,8,10 Most
reports did not specify whether this
should be calculated using current dry
body weight, pregestational IBW, or
other; some suggest adding the energy
cost of pregnancy. In this case, fetal
surveillance was the primary outcome
to modify energy or protein recom-
mendations. Higher Fe supplementa-
tion doses should have been given
during pregnancy to maintain Hb
values at greater than 10 g/dL, as well
as erythropoietin treatment.9 Fetal
growth was adequate throughout
pregnancy, except for an upper limit
estimated fetal weight at 30.2 weeks.
In pregnant womenwith CKD receiving
HD, weight gain is difﬁcult to interpret.
This patient had excessive weight gain
from 22.5 to 29.5 weeks of gestation.12
Possibly the HD was insufﬁcient. Thus,
considering fetal growth and the pa-
tient’s weight gain, the energy intake
recommendation was estimated and
maintained at 30 kcal/kg pregesta-
tional IBW.218 JOURNAL OF THE ACADEMY OF NUTRITAdverse perinatal outcomes for this
patient included polyhydramnios,
anemia, and premature rupture of
membranes, and the clinical evolution
of the newborn was not optimal
(Figure 2).
CONCLUSIONS
This is one of the few cases that reports
the challenge of applying the nutrition
care process for CKD during pregnancy.
As expected, some positive and some
adverse clinical outcomes were
observed. The renal RDN has a unique
role within the health care team
responsible for treating CKD in preg-
nancy. RDNs must provide speciﬁc
renal nutrition therapy interventions
and nutrition education and coun-
seling. Studies describing nutritional
and clinical status throughout preg-
nancy in women with CKD are urgent,
as is the evaluation of MNT with spe-
ciﬁc nutrition strategies.
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